Jade Biosciences Gears Up for Key Conference Appearances
Jade Biosciences, Inc., a pioneering biotechnology firm focused on cutting-edge therapies for autoimmune diseases, is preparing to showcase its latest developments at several significant upcoming conferences. The company, listed on Nasdaq under the ticker JBIO, is committed to addressing pressing needs in autoimmune treatment.
Scheduled Conferences
This November, Jade will participate in a series of prominent healthcare gatherings designed to highlight advancements in the biotechnology field:
Wedbush Rewind ASN Conference 2025
The first stop for Jade will be the Wedbush Rewind ASN Conference. Here, the company plans to engage in a fireside chat on November 10, discussing the implications of their lead therapies and their vision for the future.
Stifel Healthcare Conference
Following quickly on the heels of the ASN Conference, Jade will feature at the Stifel Healthcare Conference from November 11-13. A key presentation is slated for November 12 at 4:00 p.m. ET, where Jade will share insights into its current projects and future innovations.
TD Cowen Immunology & Inflammation Virtual Summit
From November 12-13, the TD Cowen Summit will showcase groundbreaking work in immunology, including Jade's presentations. On November 13, at 3:00 p.m. ET, the company aims to impress attendees with its unique approach to tackling inflammation-related diseases.
Jefferies Global Healthcare Conference
Rounding off the month, Jade will participate in the Jefferies Global Healthcare Conference taking place from November 18-20. The company is eager to engage with healthcare leaders and industry experts during its presentation on November 17 at 3:30 p.m. GMT.
How to Access Webcasts
For those not attending in person, Jade Biosciences will provide live webcasts of all presentations on its official website. Each event will also feature a replay accessible for 90 days, ensuring all interested parties can benefit from the insights shared.
About Jade Biosciences
Founded with a mission to develop best-in-class therapies, Jade Biosciences is invested in redefining treatment approaches for autoimmune diseases. The company’s leading candidate, JADE101, is currently in a Phase 1 clinical trial aimed at treating immunoglobulin A nephropathy. Furthermore, its strong pipeline includes the innovative JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and the undisclosed JADE-003 antibody discovery program, both in preclinical stages.
Company Contact Information
For media inquiries or to learn more, please reach out to Priyanka Shah at Media@JadeBiosciences.com or for investor relations, contact IR@JadeBiosciences.com. Interested parties can also reach Jade at 908-447-6134.
Frequently Asked Questions
What is the main focus of Jade Biosciences?
Jade Biosciences focuses on developing therapies for autoimmune diseases, seeking to address unmet medical needs in this area.
What upcoming events will Jade Biosciences participate in?
Jade will participate in key conferences including the Wedbush Rewind ASN Conference and the Jefferies Global Healthcare Conference, among others.
How can I access Jade Biosciences' presentations?
All presentations will be streamed live on Jade's official website, with replays available afterwards for 90 days.
What is the lead candidate of Jade Biosciences?
JADE101, which targets the cytokine APRIL, is the lead candidate and is currently in a Phase 1 clinical trial for treatment of immunoglobulin A nephropathy.
How can I contact Jade Biosciences for more information?
You can contact Jade Biosciences through their media or investor relations emails: Media@JadeBiosciences.com or IR@JadeBiosciences.com.
